Name | Company | P/L % | MPV |
|
---|---|---|---|---|
Lord Glendonbrook |
![]() |
Stryker / NYQ:SYK | 437.68% | £376,378.59 |
Lord Glendonbrook |
![]() |
Abbott Laboratories / NYQ:ABT | 424.06% | £366,840.89 |
Lord Sassoon |
![]() |
Abbott Laboratories / NYQ:ABT | 302.46% | £281,723.39 |
Lord Grabiner |
![]() |
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
Baroness Noakes |
![]() |
Smith & Nephew / NYQ:SNN | 36.22% | £95,355.70 |
Lord Mance |
![]() |
Stryker / NYQ:SYK | 35.73% | £95,011.64 |
Lord Glendonbrook |
![]() |
Smith & Nephew / NYQ:SNN | 26.43% | £88,502.38 |
Lord Londesborough |
![]() |
Abbott Laboratories / NYQ:ABT | 21.68% | £85,174.60 |
Lord Glendonbrook |
![]() |
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
Lord Howard of Rising |
![]() |
Ekf Diagnostics / LSE:EKF.L | 5.16% | £73,609.96 |
Lord Browne of Madingley | Allurion / NYQ:ALUR | -26.89% | £51,178.25 | |
Lord Glendonbrook |
![]() |
Align Technology / NMS:ALGN | -34.24% | £46,029.95 |
Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** |